Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation of our letter dated February 1, 2022, we enclose copies of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2021 published on February 2, 2022 in MINT (English) and HINDUSTAN (Hindi). We request you to take the same on record.
Earnings Call for Q3FY22 of Jubilant Ingrevia
Conference Call with Jubilant Ingrevia Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript. Jubilant Ingrevia Ltd - 543271 - Record Date For Interim Dividend
This is in continuation to our intimation dated February 1, 2022, intimating the Record Date for the purpose of Interim Dividend. In this regard, we request you to read the Record Date as February 11, 2022 in place of February 9, 2022. This is for information and record. Jubilant Ingrevia Ltd - 543271 - Declaration Of Interim Dividend For The Financial Year 2021-22
This is in continuation to our intimation dated February 1, 2022, intimating the Record Date for the purpose of Interim Dividend. In this regard, we request you to read the Record Date as February 11, 2022 in place of February 9, 2022. This is for information and record. Jubilant Ingrevia Ltd - 543271 - Board declares Interim Dividend
Jubilant Ingrevia Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 01, 2022, inter alia, has declared the Interim Dividend of Rs. 2.50 per equity share of Re. 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2021-22.The Interim Dividend will be paid/ dispatched on or before March 02, 2022. Q3FY22 Quarterly Result Announced for Jubilant Ingrevia Ltd.
Chemical and Petrochemicals company Jubilant Ingrevia announced Q3FY22 results: Q3FY22 (Consolidated): Revenue grew by 44% on YoY basis, driven by growth across product segments. Revenue from Pharma, Nutrition and Agro end use increased significantly. Speciality Chemicals revenue grew by 22% YoY driven by volume growth across products and passing-on of higher input costs. Nutrition and Health Solutions revenue grew by 37% YoY driven by higher volumes and improved price realisation. Life Sciences Chemical revenue grew by 60% YoY, driven by higher prices on account of favorable market conditions. EBITDA at Rs 222 Crore, grew by 42%, on account of strong performance of all three product segments. PAT grew by 42% YoY driven by growth in EBITDA, added by reduction in finance cost through reduction in Gross debt and optimization of Interest rates. Nine Months’FY22: Revenue grew by 51% on YoY basis, driven by growth across product segments. Speciality Chemicals revenue grew by 19% YoY driven by volume growth across product. Nutrition and Health Solutions revenue grew by 30% YoY driven by higher volumes and as well as higher prices. Life Sciences Chemical revenue grew by 80% YoY, driven by higher prices on account of improved price realization on account of favorable market conditions. EBITDA at Rs 712 Crore, grew by 68% on account of strong performance of all the three product segments and favorable market conditions in Life Sciences segment. PAT grew by 85% YoY driven by growth in EBITDA, aided by reduction in finance cost on account of reduction in Debt and optimization of Interest rates. ROCE in 9M’FY22 improved to 31.1% against 20.2% in FY21 ROE in 9M’FY22 stood at 25.2% as against 16.4% in FY21. Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said: “We are pleased to announce that in Q3’FY22 we continued to witness significant growth in our Revenue & EBITDA. We are also delighted to declared an interim dividend of Rs. 2.5 per equity share of Rs 1 each of the company amounting to Rs 39.8 Cr In our Specialty Chemicals segment we maintained strong growth across the products led by growing demand from Pharmaceutical, and Nutrition customers. In Nutrition & Health Solution the demand of Vitamin B3 improved and we placed higher volumes with improved realizations. In Life Science Chemical Segment, we continued the strong performance with healthy demand in domestic as well as in EU market. Our business team worked closely with customers and ensured that most of the increase in input cost is passed on and our supply chain team ensured the uninterrupted supplies and timely deliveries. We are pleased to inform, that in DJSI (Dow Jones Sustainability Index) Environmental Social & Governance (ESG) assessment, we scored 81 percentile in the global chemical industry and have been ranked among the top 20% chemical companies globally and amongst the Top 3 chemical companies in India. We remain excited with the growth opportunities in our businesses and are fully committed to realize them. Our strong new product pipeline developed by our in-house R&D;, our technical expertise into various chemistry platforms and long-standing relationship with global Pharmaceutical & Agrochemical customers is a strong enabler in our growth journey . With our growth capex plans shaping up we remain in course of doubling the revenue by FY’26 from the base of FY’21.” Result PDF Jubilant Ingrevia Ltd - 543271 - Intimation Of Record Date For Interim Dividend
Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors has, at its meeting held today i.e. February 1, 2022, inter alia, declared the Interim Dividend of Rs. 2.50 per equity share of Re. 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2021-22. In terms of Regulation 42 of the Listing Regulations, the Board has fixed Wednesday, February 9, 2022 as the 'Record Date' for the purpose of ascertaining eligibility of the shareholders for payment of Interim Dividend. The Interim Dividend will be paid/ dispatched on or before March 2, 2022. This is for information and record. Jubilant Ingrevia Ltd - 543271 - Board Meeting Outcome for Outcome Of Board Meeting Held On February 1, 2022
Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors has, at its meeting held today i.e. February 1, 2022, inter alia, declared the Interim Dividend of Rs. 2.50 per equity share of Re. 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2021-22. We request you to take the same on records. Jubilant Ingrevia Ltd - 543271 - Approval Of Financial Results For Quarter Ended December 31, 2021
In terms of Regulations 30, 33 and 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31, 2021 were approved by the Board of Directors of the Company at its meeting held today at 12:15 p.m. and concluded at 02.45 pm. Jubilant Ingrevia Ltd - 543271 - Board to consider Interim Dividend
In continuation to the Company''s communication dated January 24, 2022, Jubilant Ingrevia Ltd has now informed BSE that the Board of Directors shall, at its meeting scheduled to be held on February 01, 2022, inter alia, consider declaration of Interim Dividend to the members of the Company for the Financial Year 2021-22.As mentioned in the Company''s communication dated December 20, 2021, the Trading Window is closed from December 25, 2021 and shall remain closed till February 03, 2022.